Amyotrophic Lateral Sclerosis Insights

Cell and gene therapies are transforming rare disease treatment, offering new hope where options were once limited. But how do they work, and what choices exist for your community?

We're launching a special content series to help our 15k+ readers navigate this evolving landscape – and we need your voice!

In a study by Eijk et al. (2025), the safety and effects of trimetazidine on patients with amyotrophic lateral sclerosis (ALS) were assessed. The medication, known to inhibit partial fatty acid oxidation, was given to 21 participants over a 12-week period. The study primarily looked at how well patients tolerated the drug and its impact on oxidative stress markers, which are indicators of cell damage.

Results showed that 90% of participants completed the treatment, and trimetazidine was generally well-tolerated, with only 11% of adverse events possibly related to the drug. Notably, there was a significant reduction in the oxidative stress marker 8-OHdG during treatment, suggesting less cellular damage. Additionally, patients experienced a decrease in resting energy expenditure, which could indicate improved metabolic efficiency. These promising findings support the need for a larger, more controlled study to further explore trimetazidine's potential benefits for ALS patients.